Neuberg centre for genomic medicine (NCGM) announced the launch of the most cutting edge and fastest prenatal diagnostic test called the Prenatal Aneuploidy NCG test (PAN Test) and an upgraded version of Chromosomal Microarray Analysis test with launch of Cyto-ONE test for the first time in India with an aim to providing better sensitivity, better detection and expanding scope and coverage with better technology. Neuberg’s PAN test and Cyto-ONE test are innovative prenatal diagnostic tests that are designed to provide better coverage of disorders in the fetus without compromising on turnaround time or cost. These tests are developed by Neuberg centre for genomic medicine, and they represent significant upgrades to existing technologies for diagnosing fetal abnormalities.

The PAN test is capable of detecting abnormalities on all chromosomes and sub-chromosomal regions, providing comprehensive answers for doctors and expecting mothers who wish to get most robust and exhaustive diagnostic results in the shortest time without the need for getting multiple tests done. The Cyto-One test is a high resolution microarray based test that will transform the realm of definitive diagnosis. This test is a major upgrade to the currently available microarray tests with its over 1 million probes, higher detection rates and lower failure rates. It will help doctors get better quality diagnostic results in both- prenatal and postnatal settings.

The advantage is that the new PAN test has better sensitivity and detection capabilities than the current QF-PCR test. It can detect more disorders and covers 22 chromosomal instead of just 5, which expands its scope and coverage. The test has a quick turnaround time of 48-72 hours and at no additional cost, making it more accessible to doctors and patients. This improved technology allows for better diagnosis and faster testing. Clinicians can make better decisions based on positive outcomes from the test. Cyto-One test is an upgraded version of the microarray test which is currently available in the market and has not been upgraded since a long time. The Cyto-One test shall support doctors in their decision making by allowing them to initiate quick intervention in at-risk mothers and in finding out the causes of recurrent pregnancy losses. It will also support the doctors in deciding the best therapeutic and management approach in babies with conditions such as autism, intellectual disability etc without compromising on turnaround time and cost.

The PAN test and Cyto-One test are a breakthrough in the field of diagnostics, enabling the detection of disorders early on. This is a significant step towards better healthcare, especially in a country like India, where access to healthcare is limited. The launch of these tests is a testament to Neuberg’s commitment to providing the best solutions for diagnostics and improving the health outcomes of people.

Speaking about the launch, Dr. GSK Velu, Chairman & Managing Director, Neuberg Diagnostics, said, “We understand that the cost of diagnostics is a significant concern for people in India, and we believe that everyone should have access to affordable and high-quality healthcare. Our PAN test and Cyto-ONE test are priced competitively, making them accessible to people from all walks of life. We are committed to providing the best solutions for diagnostics that are both accurate and affordable.”

According to Dr. Parth Shah, Senior Scientific Advisor, NCGM, “The PAN test and the Cyto-ONE test are some of the most comprehensive solutions available in the market. These tests enable better detection of disorders and abnormalities, providing doctors with access to diagnose abnormalities in the fetus and babies. Through these tests expecting mothers and doctors now have access to the latest technology which has been significantly been improved by Neuberg through the addition of more probes, more markers, and updated analysis.”

Neuberg’s commitment to research and development, combined with its focus on affordability and accessibility, is driving its efforts to improve the health and well-being of people worldwide.